• Consensus Rating: Buy
  • Consensus Price Target: $8.00
  • Forecasted Upside: 292.16%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.04
▼ -0.27 (-11.69%)

This chart shows the closing price for IMMP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Immutep Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMMP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMMP

Analyst Price Target is $8.00
▲ +292.16% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Immutep in the last 3 months. The average price target is $8.00, with a high forecast of $10.00 and a low forecast of $6.00. The average price target represents a 292.16% upside from the last price of $2.04.

This chart shows the closing price for IMMP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Immutep. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/23/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/18/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/17/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/16/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/16/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/27/2024Robert W. BairdLower TargetOutperform ➝ Outperform$7.00 ➝ $6.00Low
5/17/2024Capital One FinancialInitiated CoverageOverweight$10.00Low
8/28/2023Robert W. BairdReiterated RatingOutperform ➝ Outperform$7.00Low
8/2/2023Robert W. BairdInitiated CoverageOutperform$7.00Low
5/17/2023Maxim GroupBoost Target$8.00 ➝ $10.00Low
12/2/2021Jefferies Financial GroupInitiated CoverageBuyMedium
8/3/2021LADENBURG THALM/SH SHInitiated CoverageBuy$8.30Medium
6/10/2021Alliance Global PartnersBoost TargetBuy$6.00 ➝ $9.00Low
1/26/2021Alliance Global PartnersBoost TargetBuy$5.00 ➝ $6.00Medium
12/14/2020Maxim Group$4.00 ➝ $8.00N/A
11/11/2020Maxim GroupBoost TargetPositive ➝ Buy$2.00 ➝ $4.00High
9/22/2020Alliance Global PartnersInitiated CoverageBuyLow
6/2/2020Maxim GroupReiterated RatingBuy$2.00Low
4/30/2020Maxim GroupInitiated CoverageBuy$2.00Low
9/24/2019Maxim GroupReiterated RatingBuy$4.00High
7/31/2019Maxim GroupSet TargetBuy$4.00N/A
(Data available from 7/16/2019 forward)

News Sentiment Rating

0.78 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/19/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/18/2024
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/17/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/18/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/17/2024
  • 3 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/17/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/16/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/16/2024

Current Sentiment

  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Immutep logo
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.
Read More

Today's Range

Now: $2.04
Low: $1.96
High: $2.22

50 Day Range

MA: $2.61
Low: $1.87
High: $3.23

52 Week Range

Now: $2.04
Low: $1.58
High: $3.34

Volume

965,683 shs

Average Volume

273,795 shs

Market Capitalization

$242.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.2

Frequently Asked Questions

What sell-side analysts currently cover shares of Immutep?

The following Wall Street sell-side analysts have issued stock ratings on Immutep in the last twelve months: Capital One Financial Co., and Robert W. Baird.
View the latest analyst ratings for IMMP.

What is the current price target for Immutep?

2 Wall Street analysts have set twelve-month price targets for Immutep in the last year. Their average twelve-month price target is $8.00, suggesting a possible upside of 292.2%. Capital One Financial Co. has the highest price target set, predicting IMMP will reach $10.00 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $6.00 for Immutep in the next year.
View the latest price targets for IMMP.

What is the current consensus analyst rating for Immutep?

Immutep currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IMMP will outperform the market and that investors should add to their positions of Immutep.
View the latest ratings for IMMP.

What other companies compete with Immutep?

How do I contact Immutep's investor relations team?

Immutep's physical mailing address is LEVEL 12 95 PITT STREET, SYDNEY C3, 2000. The biotechnology company's listed phone number is (128) 315-7003 and its investor relations email address is [email protected]. The official website for Immutep is www.immutep.com. Learn More about contacing Immutep investor relations.